MAR 03, 2018 12:58 AM PST

Doubting the Wonder Drug

WRITTEN BY: Nouran Amin

Baclofen is a drug used to treat an alcohol use disorder. It has long been debuted as the "Wonder Drug" for several of its unique characteristics. For one, baclofen is secreted from the kidneys, not the liver which is particularly advantageous to individuals suffering from liver disease due to an alcohol use disorder (AUD).


Image: University of Liverpool via TechExplorist.com

Historically, baclofen was developed by Dr. Heinrich Keberle in 1962 initially to treat epilepsy. But because of its muscle relaxant properties, it was used instead for the treatment of spasticity particularly in cases related to multiple sclerosis. It was also used in spinal cord injuries for painful muscle spasms.

So, what is baclofen? Baclofen is a GABA receptor agonist that works to suppress the nervous system from an overdose. It's hypothesized that individuals with an AUD are GABA receptor-deficient and thus taking baclofen may reverse this complication and reduce alcohol dependence.

Image Source: ArcaGeorgia.com

However, the mechanism of action of baclofen particularly in treating AUD, still remains unknown. Such mystery encouraged researchers at the University of Liverpool to re-examine the wonder drug.

Originally, the support of baclofen in treating AUD comes from clinical studies showing a decrease in mood swings, depression, and anxiety. Participants also experienced a reduction in alcohol craving.

Now, addiction researchers at the University of Liverpool are questioning the effectiveness of baclofen. Lead researchers, Dr. Abi Rose and Dr. Andy Jones performed a meta-analysis study of roughly 12 clinical trials to see if baclofen holds true in treating alcohol dependence. The purpose was to re-examine the original clinical study that showed support for baclofen and to compare this study across various variables including the placement of a placebo. The meta-analysis study merged all results together to ensure accuracy and reliability of the effectiveness of baclofen.

The addiction research team found that alcohol dependence was reduced in comparison to a placebo. However, that was not sufficient enough as baclofen did not increase alcohol abstinence over a period of days. It was also found that it did not decrease alcohol craving, anxiety, or depression.

Even though the outcomes of this study were more accurate in comparison to the original clinical trial, there are still issues that need to be examined in these current clinical trials. Dr. Rose of the addiction team states, "The existing trials also differ on a number of factors, such as the dose of baclofen given and the length of treatment. Importantly, the pharmacokinetics of baclofen (how it moves in the body) are not well-understood, so there may be individual factors influencing the effectiveness of baclofen that we do not yet understand." The research claims that the use of baclofen in the treatment of an AUD is ‘premature’.

The results of this study were published in the Addiction journal.

Sources: Science Daily, Addiction

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 24, 2018
Drug Discovery
OCT 24, 2018
Silver Nanoparticles Coat Anti-seizure Drugs To Combat Brain-Eating Amoebae
Since Halloween is around the corner, it is science-fiction season and some may choose to celebrate by watching movies featuring brain-eating zombies. Howe...
NOV 13, 2018
Drug Discovery
NOV 13, 2018
Clinical Trial Drug For a Rare Neurodegenrative Disease Proven Unsuccessful
Niemann-Pick type C (NPC) is a rare and fatal neurodegenerative disease. Symptoms of the condition include loss of balance, difficulty swallowing, seizures...
DEC 09, 2018
Drug Discovery
DEC 09, 2018
Insect Venom Can Someday Combat Antibiotic-Resistant Infections
Insect venom, such as those secreted by wasps and bees, are considered an insect’s immune system defense because of its richness in bacterial killing...
DEC 20, 2018
Health & Medicine
DEC 20, 2018
Common Medication Regimens for Sarcoidosis
Sarcoidosis is a granulomatous disease that most commonly affects the lungs, but any organ system can be involved. It is most often found and diagnosed in...
JAN 15, 2019
Immunology
JAN 15, 2019
A Possible Key to Severe Flu
By studying the impact that NPY and its receptor Y1R have on influenza in mice, the research group has now discovered that NPY produced in lung phagocytes can aggravate influenza....
JAN 24, 2019
Drug Discovery
JAN 24, 2019
Drug Blocks Toxic-Protein Production in ALS
Individuals with ALS, frontotemporal dementia, carry a mutation in the gene C9orf72—resulting in repeated DNA sequences. These repetitions result in ...
Loading Comments...